AVITA Medical (RCEL)
Market Price (2/7/2026): $3.925 | Market Cap: $111.4 MilSector: Health Care | Industry: Life Sciences Tools & Services
AVITA Medical (RCEL)
Market Price (2/7/2026): $3.925Market Cap: $111.4 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Targeted Therapies, and Regenerative Therapies. | Weak multi-year price returns2Y Excs Rtn is -117%, 3Y Excs Rtn is -126% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -42 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -58% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 14.59, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% | Weak revenue growthRev Chg QQuarterly Revenue Change % is -13% | |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -47%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -51% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -48% | ||
| Key risksRCEL key risks include [1] a crippling backlog of unpaid CMS claims for its RECELL product that has severely impacted revenue, Show more. |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Targeted Therapies, and Regenerative Therapies. |
| Weak multi-year price returns2Y Excs Rtn is -117%, 3Y Excs Rtn is -126% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 14.59, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -42 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -58% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -13% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -47%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -51% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -48% |
| Key risksRCEL key risks include [1] a crippling backlog of unpaid CMS claims for its RECELL product that has severely impacted revenue, Show more. |
Qualitative Assessment
AI Analysis | Feedback
AVITA Medical (RCEL) stock has remained largely at the same level since 10/31/2025 because of the following key factors:
1. Strong 2026 Revenue Guidance and Preliminary FY2025 Results
AVITA Medical announced preliminary full-year 2025 revenue of approximately $71.6 million, marking an 11% increase from 2024. More importantly, the company provided an optimistic 2026 revenue outlook, projecting between $80 million and $85 million. This forecast represents a growth of approximately 12% to 19% compared to 2025, signaling anticipated continued expansion.
2. Strengthened Financial Position with New Credit Facility
On January 13, 2026, AVITA Medical significantly enhanced its financial flexibility by securing a new five-year credit facility for up to $60 million with Perceptive Advisors. An initial $50 million was immediately funded, primarily to repay existing debt. This move strengthened the company's capital structure and included a reset of revenue covenants to more appropriate and manageable levels, addressing prior financial concerns.
Show more
1. Strong 2026 Revenue Guidance and Preliminary FY2025 Results
AVITA Medical announced preliminary full-year 2025 revenue of approximately $71.6 million, marking an 11% increase from 2024. More importantly, the company provided an optimistic 2026 revenue outlook, projecting between $80 million and $85 million. This forecast represents a growth of approximately 12% to 19% compared to 2025, signaling anticipated continued expansion.
2. Strengthened Financial Position with New Credit Facility
On January 13, 2026, AVITA Medical significantly enhanced its financial flexibility by securing a new five-year credit facility for up to $60 million with Perceptive Advisors. An initial $50 million was immediately funded, primarily to repay existing debt. This move strengthened the company's capital structure and included a reset of revenue covenants to more appropriate and manageable levels, addressing prior financial concerns.
Show more
Stock Movement Drivers
Fundamental Drivers
The 0.8% change in RCEL stock from 10/31/2025 to 2/6/2026 was primarily driven by a 12.2% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2062026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.87 | 3.90 | 0.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 75 | 72 | -3.3% |
| P/S Multiple | 1.4 | 1.5 | 12.2% |
| Shares Outstanding (Mil) | 26 | 28 | -7.1% |
| Cumulative Contribution | 0.8% |
Market Drivers
10/31/2025 to 2/6/2026| Return | Correlation | |
|---|---|---|
| RCEL | 0.8% | |
| Market (SPY) | 1.3% | 23.4% |
| Sector (XLV) | 9.3% | -6.8% |
Fundamental Drivers
The -26.4% change in RCEL stock from 7/31/2025 to 2/6/2026 was primarily driven by a -21.2% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2062026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.30 | 3.90 | -26.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 72 | 72 | 1.0% |
| P/S Multiple | 1.9 | 1.5 | -21.2% |
| Shares Outstanding (Mil) | 26 | 28 | -7.5% |
| Cumulative Contribution | -26.4% |
Market Drivers
7/31/2025 to 2/6/2026| Return | Correlation | |
|---|---|---|
| RCEL | -26.4% | |
| Market (SPY) | 9.6% | 17.3% |
| Sector (XLV) | 21.5% | -9.6% |
Fundamental Drivers
The -57.1% change in RCEL stock from 1/31/2025 to 2/6/2026 was primarily driven by a -61.2% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2062026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.10 | 3.90 | -57.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 60 | 72 | 20.6% |
| P/S Multiple | 3.9 | 1.5 | -61.2% |
| Shares Outstanding (Mil) | 26 | 28 | -8.5% |
| Cumulative Contribution | -57.1% |
Market Drivers
1/31/2025 to 2/6/2026| Return | Correlation | |
|---|---|---|
| RCEL | -57.1% | |
| Market (SPY) | 15.8% | 24.1% |
| Sector (XLV) | 8.8% | 8.6% |
Fundamental Drivers
The -58.2% change in RCEL stock from 1/31/2023 to 2/6/2026 was primarily driven by a -79.1% change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2062026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.34 | 3.90 | -58.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 32 | 72 | 126.3% |
| P/S Multiple | 7.3 | 1.5 | -79.1% |
| Shares Outstanding (Mil) | 25 | 28 | -11.9% |
| Cumulative Contribution | -58.2% |
Market Drivers
1/31/2023 to 2/6/2026| Return | Correlation | |
|---|---|---|
| RCEL | -58.2% | |
| Market (SPY) | 76.2% | 26.3% |
| Sector (XLV) | 23.8% | 12.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| RCEL Return | -36% | -45% | 108% | -7% | -73% | 14% | -79% |
| Peers Return | 1% | -33% | 52% | 1% | -1% | -13% | -11% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 81% |
Monthly Win Rates [3] | |||||||
| RCEL Win Rate | 33% | 25% | 67% | 50% | 25% | 50% | |
| Peers Win Rate | 55% | 42% | 58% | 48% | 48% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| RCEL Max Drawdown | -37% | -62% | -2% | -44% | -74% | -5% | |
| Peers Max Drawdown | -15% | -46% | -23% | -34% | -35% | -14% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: IART, ORGO, MDXG, VCEL, INCY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/6/2026 (YTD)
How Low Can It Go
| Event | RCEL | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -84.1% | -25.4% |
| % Gain to Breakeven | 527.2% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -63.4% | -33.9% |
| % Gain to Breakeven | 173.3% | 51.3% |
| Time to Breakeven | 104 days | 148 days |
Compare to IART, ORGO, MDXG, VCEL, INCY
In The Past
AVITA Medical's stock fell -84.1% during the 2022 Inflation Shock from a high on 1/26/2021. A -84.1% loss requires a 527.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About AVITA Medical (RCEL)
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
AI Analysis | Feedback
Here are 1-3 brief analogies for AVITA Medical (RCEL):
- Intuitive Surgical (ISRG) for skin regeneration. (Like Intuitive Surgical provides a system for advanced surgery, AVITA offers a system for advanced skin repair and regeneration.)
- Organogenesis (ORGO) for autologous, spray-on skin cell therapies. (Similar to Organogenesis in advanced wound care, but specializing in a rapid, on-site, patient-derived spray-on solution for skin.)
- Cochlear (COH) for skin regeneration. (Like Cochlear provides highly specialized, transformative devices for hearing, AVITA offers a high-tech system that regenerates skin for specific medical needs.)
AI Analysis | Feedback
- RECELL System: A medical device used to prepare a Regenerative Epidermal Suspension (RES) from a patient's own skin, facilitating skin regeneration for acute thermal burns and full-thickness skin defects.
- RECELL GO: The next generation of the RECELL System, designed for enhanced usability and efficiency in preparing the Regenerative Epidermal Suspension for various skin defects.
AI Analysis | Feedback
```htmlAVITA Medical (RCEL) sells primarily to other companies, specifically healthcare institutions and related entities.
Based on their latest SEC filings, AVITA Medical does not disclose any single customer accounting for 10% or more of their total revenue. Therefore, specific names of major customer companies cannot be identified.
However, their sales efforts are directed towards the following categories of organizations:
- Hospitals and Burn Centers: These are the primary direct purchasers and end-users of AVITA Medical's RECELL System in the United States, where the devices are used for skin regeneration procedures.
- Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs): While not direct end-users, GPOs and IDNs are critical entities in the U.S. healthcare system. AVITA Medical establishes relationships with these organizations to facilitate broader market access and streamline purchasing agreements for their member hospitals and healthcare facilities.
- International Distributors and Commercial Partners: Outside the United States, AVITA Medical relies on third-party companies that act as distributors and commercial partners. These companies purchase AVITA Medical's products and then sell them to healthcare facilities within their respective regions.
AI Analysis | Feedback
nullAI Analysis | Feedback
Cary Vance, Interim Chief Executive Officer
Mr. Vance was appointed Interim Chief Executive Officer in October 2025 and also serves as Chairman of the company since August 2025, having been a Director since 2023. He is an accomplished healthcare industry executive with over 30 years of experience in driving value creation and bringing breakthrough medical technologies to market. He previously served as President and CEO of several innovative companies, including PhotoniCare, Inc., Titan Medical Inc., Optiscan Biomedical, Hansen Medical, and XCath. Mr. Vance also held various global leadership roles at Teleflex, Covidien, and GE HealthCare.
David O'Toole, Chief Financial Officer
Mr. O'Toole was appointed Chief Financial Officer in June 2023. He is an accomplished financial executive with over 30 years of experience in global corporate finance, capital markets, and accounting across biotech and life sciences companies. Mr. O'Toole most recently served as CFO of Opiant Pharmaceuticals, a biopharmaceutical company that was acquired by Indivior PLC in March 2023. Prior to that, he was the CFO of Soleno Therapeutics, and previously held CFO roles for three other publicly traded life sciences companies. Before his CFO experience, he spent 24 years in public accounting, including 16 years with Deloitte & Touche.
Nicole Linda Kelsey, Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary
Ms. Kelsey has served as Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary of AVITA Medical since 2024. Her previous roles include Chief Legal Officer and Secretary of Amyris Inc, General Counsel and Secretary at Criteo S.A., and Principal Legal Counsel for Medtronic Inc.
Niraj Doshi, Ph.D., Senior Vice President - Product Development & Program Management
Dr. Doshi has been Senior Vice President - Product Development & Program Management since 2019.
Debbie Garner, Senior Vice President - Global Marketing & Strategy
Ms. Garner has served as Senior Vice President - Global Marketing & Strategy since 2023.
AI Analysis | Feedback
The key risks to AVITA Medical's (RCEL) business are primarily centered around reimbursement challenges, financial instability, and competitive market pressures.
- CMS Reimbursement Delays and Claims Backlog: AVITA Medical has experienced significant revenue declines due to prolonged delays in pricing decisions by the Centers for Medicare & Medicaid Services (CMS). This has led to a substantial backlog of unpaid provider claims for its RECELL wound care product, creating uncertainty among providers regarding payment and subsequently reducing the utilization of RECELL procedures. These delays directly impacted the company's financial performance, leading to a reduction in 2025 H1 RECELL demand by 20% and revised revenue guidance. This issue has also triggered investigations into possible securities fraud and legal risks, which could result in costly settlements or reputational damage. The successful resolution of this claims backlog is considered a critical factor for the company's long-term viability.
- Liquidity Challenges and Inability to Achieve and Maintain Profitability: AVITA Medical has a history of significant losses and anticipates continued losses, with uncertainty around achieving or maintaining profitability. The company faces liquidity issues, with limited cash reserves and ongoing operating cash burn, necessitating further capital raises that could dilute existing shareholders. As of early 2025, the company had a limited cash runway, reportedly only a few quarters of cash remaining, alongside a notable debt. Missed revenue estimates and challenges in meeting financial goals amplify concerns about its financial stability and the potential for unfavorable financing terms.
- Competitive Pressures and Market Adoption Challenges: The company operates in a highly competitive wound care market, facing pressure from competitors such as TELA Bio and Spectral AI, which threaten its market share. Despite launching new products like RECELL GO Mini and Cohealyx, the impact on revenue remains unproven, and there are concerns about the lack of diversification in its acute wound care portfolio. There is also skepticism regarding whether the marginal improvements offered by RECELL are sufficient to change established practices among healthcare professionals, leading to potentially slow adoption rates that require significant marketing and education efforts.
AI Analysis | Feedback
nullAI Analysis | Feedback
AVITA Medical (RCEL) operates in the acute wound care and regenerative medicine markets with its key products, including the RECELL System (and RECELL GO), PermeaDerm, and Cohealyx. The addressable markets for these products vary by region and specific application. The addressable markets for AVITA Medical's main products and services are as follows:- United States Acute Wound Care (RECELL, Cohealyx, PermeaDerm): AVITA Medical targets an addressable market of approximately $1.3 billion within approximately 200 high-value U.S. burn and trauma centers. More broadly, the total addressable market (TAM) for AVITA's portfolio across all U.S. burn and trauma hospitals is estimated to be about $3.5 billion. This larger market includes a burn market TAM exceeding $1.5 billion (comprising $400 million for RECELL, $100 million for PermeaDerm, and over $1 billion for Cohealyx) and a full-thickness wound TAM exceeding $2 billion. The company aims to expand its U.S. acute wound care market TAM from $1.3 billion in 2023 to $3.5 billion by 2025.
- United States Vitiligo Treatment (RECELL): The market opportunity for stable depigmented vitiligo lesions was approximately $1.5 billion in 2022 in the U.S..
- European Acute Wound Care (RECELL GO): With CE Mark approval for RECELL GO, AVITA Medical anticipates opening a European market estimated at $1.5 billion. The CE Mark enables commercialization across Europe, starting with Germany, Italy, and the United Kingdom.
AI Analysis | Feedback
AVITA Medical (RCEL) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market expansions:
- Expansion of the RECELL System in Acute Wound Care: The company is strategically focused on broadening the deployment and utilization of its RECELL System, including RECELL GO, across the U.S. acute wound care market, specifically targeting burn, trauma, and surgical environments. This market is valued at approximately $1.3 billion. The RECELL System has demonstrated significant clinical benefits, such as reducing hospital stays by 36% in burn patients, and has received New Technology Add-on Payment (NTAP) approval from CMS for trauma wounds in the hospital inpatient setting, which is expected to bolster its adoption.
- Growth of Recently Launched Products (Cohealyx and PermeaDerm): AVITA Medical expects significant contributions from its newer products, Cohealyx and PermeaDerm. Cohealyx is a collagen-based dermal matrix for graft-ready dermis, while PermeaDerm serves as a protective biosynthetic cover. These products, either directly launched or marketed through partnerships, are integral to AVITA's strategy of building a comprehensive full-thickness wound care portfolio, aiming for better clinical integration and market reach.
- International Expansion: The company anticipates revenue growth from expanding its market presence internationally. This includes leveraging new products like Cohealyx and PermeaDerm to penetrate global markets. A notable milestone supporting this driver is the CE Mark approval for RECELL GO in Europe, which is expected to contribute to future revenue streams.
- Resolution of Reimbursement Challenges: AVITA Medical has faced headwinds due to reimbursement disruptions for its RECELL System, particularly with Medicare coding and payment interruptions that led to a backlog of claims and a revision of 2025 revenue guidance. As the company works towards reimbursement normalization and surgeons regain confidence in payment, the resolution of these issues is expected to drive a return to more consistent demand and utilization of the RECELL System, thereby increasing revenue.
- Launch of New Products such as RECELL GO mini: Future product launches, such as the planned FDA approval of RECELL GO mini, are expected to provide additional avenues for revenue growth. This expansion of the product portfolio caters to evolving market needs and reinforces AVITA Medical's position in regenerative medicine.
AI Analysis | Feedback
Share Repurchases
- AVITA Medical repurchased $1.37 million of common stock in 2024.
- The company repurchased $655,000 of common stock in 2023.
Share Issuance
- In August 2025, AVITA Medical successfully completed a private placement in Australia, raising approximately US$15 million (A$23 million) through the issuance of 17.2 million new CHESS Depositary Interests (CDIs).
- As part of an August amendment to its loan facility, the company issued 400,000 shares of common stock to Orbimed, resulting in a non-cash charge of $2.2 million in Q3 2025.
- AVITA Medical issued $69.17 million, $900,000, $957,000, and $2.14 million in common stock in 2021, 2022, 2023, and 2024, respectively.
Inbound Investments
- In August 2025, AVITA Medical secured approximately US$15 million from Australian institutional and professional investors through a private placement of CHESS Depositary Interests (CDIs).
- The company received $38 million out of an approximately $53 million BARDA (Biomedical Advanced Research and Development Authority) funding for product development and inventory as of March 2023.
- A non-cash charge of $2.2 million was related to the issuance of 400,000 shares of common stock to Orbimed in Q3 2025, as part of an amendment to the loan facility.
Outbound Investments
- AVITA Medical's purchase of investments amounted to $24.50 million in 2024.
- The company made significant purchases of investments totaling $78.76 million in 2023.
- In 2022, outbound investments in the form of investment purchases were $74.36 million.
Capital Expenditures
- Capital expenditures (PPE Investments) were $9.17 million in 2024.
- In 2023, capital expenditures totaled $1.38 million.
- Capital expenditures in 2022 were $452,000.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| AVITA Medical Earnings Notes | 12/16/2025 | |
| Can AVITA Medical Stock Recover If Markets Fall? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 8.21 |
| Mkt Cap | 0.8 |
| Rev LTM | 429 |
| Op Inc LTM | 19 |
| FCF LTM | 3 |
| FCF 3Y Avg | 24 |
| CFO LTM | 63 |
| CFO 3Y Avg | 46 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 14.4% |
| Rev Chg 3Y Avg | 15.3% |
| Rev Chg Q | 18.3% |
| QoQ Delta Rev Chg LTM | 4.4% |
| Op Mgn LTM | 2.3% |
| Op Mgn 3Y Avg | 3.4% |
| QoQ Delta Op Mgn LTM | 2.9% |
| CFO/Rev LTM | 11.3% |
| CFO/Rev 3Y Avg | 10.4% |
| FCF/Rev LTM | 3.5% |
| FCF/Rev 3Y Avg | 2.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.8 |
| P/S | 1.7 |
| P/EBIT | 13.7 |
| P/E | 18.3 |
| P/CFO | 10.5 |
| Total Yield | 0.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 0.9% |
| D/E | 0.1 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -11.3% |
| 3M Rtn | -6.8% |
| 6M Rtn | -10.7% |
| 12M Rtn | -39.4% |
| 3Y Rtn | 12.9% |
| 1M Excs Rtn | -11.5% |
| 3M Excs Rtn | -4.0% |
| 6M Excs Rtn | -23.1% |
| 12M Excs Rtn | -54.9% |
| 3Y Excs Rtn | -41.2% |
Price Behavior
Price Behavior
| Market Price | $3.90 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 10/02/2019 | |
| Distance from 52W High | -63.1% | |
| 50 Days | 200 Days | |
| DMA Price | $3.69 | $5.07 |
| DMA Trend | down | down |
| Distance from DMA | 5.7% | -23.1% |
| 3M | 1YR | |
| Volatility | 51.6% | 91.7% |
| Downside Capture | 88.51 | 192.20 |
| Upside Capture | 92.90 | 78.59 |
| Correlation (SPY) | 23.0% | 24.0% |
RCEL Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.55 | 1.57 | 1.22 | 1.63 | 1.15 | 1.42 |
| Up Beta | -0.21 | 0.79 | 0.62 | 0.72 | 1.21 | 1.44 |
| Down Beta | 2.02 | 1.72 | 1.59 | 1.96 | 0.68 | 0.76 |
| Up Capture | 439% | 290% | 165% | 112% | 80% | 293% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 11 | 20 | 26 | 55 | 107 | 352 |
| Down Capture | -105% | 65% | 89% | 183% | 141% | 112% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 8 | 18 | 30 | 63 | 133 | 378 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RCEL | |
|---|---|---|---|---|
| RCEL | -58.8% | 91.8% | -0.58 | - |
| Sector ETF (XLV) | 7.7% | 17.3% | 0.27 | 8.6% |
| Equity (SPY) | 15.4% | 19.4% | 0.61 | 23.9% |
| Gold (GLD) | 73.9% | 24.8% | 2.19 | 4.9% |
| Commodities (DBC) | 8.9% | 16.6% | 0.34 | 11.1% |
| Real Estate (VNQ) | 4.6% | 16.5% | 0.10 | 14.8% |
| Bitcoin (BTCUSD) | -33.5% | 42.9% | -0.83 | 22.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RCEL | |
|---|---|---|---|---|
| RCEL | -31.3% | 73.6% | -0.19 | - |
| Sector ETF (XLV) | 8.1% | 14.5% | 0.37 | 18.5% |
| Equity (SPY) | 14.4% | 17.0% | 0.68 | 32.3% |
| Gold (GLD) | 21.4% | 16.9% | 1.03 | 6.9% |
| Commodities (DBC) | 11.5% | 18.9% | 0.49 | 10.2% |
| Real Estate (VNQ) | 5.0% | 18.8% | 0.17 | 24.9% |
| Bitcoin (BTCUSD) | 13.9% | 57.8% | 0.46 | 17.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RCEL | |
|---|---|---|---|---|
| RCEL | -5.8% | 176.0% | 0.30 | - |
| Sector ETF (XLV) | 10.9% | 16.5% | 0.54 | 16.0% |
| Equity (SPY) | 15.4% | 17.9% | 0.74 | 19.2% |
| Gold (GLD) | 15.7% | 15.5% | 0.84 | 3.6% |
| Commodities (DBC) | 8.0% | 17.6% | 0.37 | 8.2% |
| Real Estate (VNQ) | 6.0% | 20.7% | 0.25 | 16.5% |
| Bitcoin (BTCUSD) | 67.1% | 66.6% | 1.07 | 7.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | 10.9% | 10.0% | 3.8% |
| 8/7/2025 | -21.0% | 7.8% | -21.7% |
| 5/8/2025 | -25.3% | -31.7% | -34.5% |
| 2/13/2025 | 20.4% | 11.0% | 2.8% |
| 11/7/2024 | -3.6% | 1.5% | 10.5% |
| 8/8/2024 | 20.7% | 17.4% | 14.4% |
| 5/13/2024 | 4.4% | -2.2% | 6.0% |
| 2/22/2024 | 0.5% | 6.6% | -7.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 10 | 11 |
| # Negative | 9 | 10 | 9 |
| Median Positive | 4.4% | 9.2% | 11.4% |
| Median Negative | -3.6% | -6.9% | -19.0% |
| Max Positive | 20.7% | 30.7% | 43.9% |
| Max Negative | -25.3% | -31.7% | -34.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/13/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 02/22/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 02/28/2022 | 10-KT |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | McNamara, Robert | Direct | Buy | 8292025 | 4.50 | 10,000 | 45,000 | 390,470 | Form | |
| 2 | O'Toole, David D | CFO | Direct | Buy | 8262025 | 4.52 | 2,000 | 9,040 | 143,090 | Form |
| 3 | McNamara, Robert | Direct | Buy | 8202025 | 5.00 | 10,000 | 50,000 | 383,855 | Form | |
| 4 | O'Toole, David D | CFO | Direct | Buy | 8122025 | 4.81 | 2,000 | 9,620 | 142,650 | Form |
| 5 | McNamara, Robert | Direct | Buy | 3102025 | 8.30 | 11,000 | 91,300 | 471,017 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.